文献速递炎症性肠病

乌帕替尼与托法替布在难治性中重度溃疡性结肠炎中的疗效比较

Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-09-09

该多中心回顾性队列研究纳入350例生物制剂经治的中重度溃疡性结肠炎患者(托法替布246例,乌帕替尼104例),采用逆概率加权分析比较两者疗效。结果显示乌帕替尼在第12周和第24周的无激素缓解率、临床缓解率和生化缓解率均显著优于托法替布,两组住院和早期结肠切除率无显著差异,未发现新安全信号。

要点

  • 乌帕替尼第12周和第24周无激素缓解率均显著高于托法替布(aOR均为2.2)。
  • 乌帕替尼同时点的临床缓解和生化缓解率约为托法替布的2倍。
  • 两组IBD相关住院和早期结肠切除率无显著差异,未发现新安全信号。

核心结论

  • 在难治性中重度溃疡性结肠炎患者中,乌帕替尼可能较托法替布带来更好的短期和中期的临床与生化结局。

研究设计与样本

  • 多中心回顾性队列研究,共纳入350例溃疡性结肠炎患者(托法替布246例,乌帕替尼104例;平均年龄38.6±13.8岁;中位随访11个月)。
  • 采用逆概率加权分析对人口学特征、基线Mayo评分、基线C反应蛋白和粪钙卫蛋白以及合并使用皮质类固醇进行校正。

主要发现

  • 乌帕替尼组第12周无激素缓解的校正比值比为2.2(95%CI 1.2-4.1),第24周为2.2(95%CI 1.2-3.9),均显著高于托法替布组。
  • 乌帕替尼组同时点临床缓解的比值比约为托法替布的2倍(95%CI 1.3-4.3;95%CI 1.0-3.4)。
  • 乌帕替尼组同时点生化缓解的比值比约为托法替布的2倍(95%CI 1.3-4.4;95%CI 1.2-4.0)。
  • 两组IBD相关住院率和早期结肠切除率无显著差异,未观察到新的安全信号。

关键数值与推荐

  • 无激素缓解定义为临床缓解且C反应蛋白≤5 mg/L,并且至少30天未使用类固醇。
  • 生化缓解定义为C反应蛋白≤5 mg/L且粪钙卫蛋白≤250 μg/g。

临床怎么用

  • 对于生物制剂经治的难治性中重度溃疡性结肠炎,乌帕替尼可能作为优于托法替布的诱导和维持治疗选择。
  • 治疗决策时需结合患者个体情况,并关注短期和中期无激素缓解及生化缓解目标。

局限性

  • 本研究为回顾性队列研究,可能存在未测量的混杂因素。
  • 中位随访时间仅11个月,长期疗效和安全性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Comparative data on the effectiveness of tofacitinib (TOFA) and upadacitinib (UPA) in ulcerative colitis (UC) remain limited. We conducted a multicenter, retrospective cohort study to evaluate and compare the short- and mid-term effectiveness of TOFA and UPA in bio-experienced, moderate-to-severe UC. METHODS: Inverse probability weighting analysis was performed for demographics, baseline Mayo score, and baseline C-reactive protein [CRP] and fecal calprotectin [FCal], as well as concomitant corticosteroid use between the 2 treatment groups. The coprimary outcome was week 12 and 24 corticosteroid-free remission (CSFR) defined as clinical remission (CR) and CRP ≤5 mg/L, as well as not receiving steroids ≥30 days. We also assessed the rate of CR and biochemical remission (defined as CRP ≤5 mg/L and FCal ≤ 250 μg/g) during the first 6 months of therapy. RESULTS: A total of 350 patients with UC (246 TOFA, 104 UPA; mean age, 38.6 ±13.8 years; median follow-up, 11 months) were enrolled in the study. The likelihood of achieving CSFR at both week 12 (adjusted odds ratio [aOR], 2.2; 95% confidence interval [CI], 1.2-4.1) and week 24 (aOR, 2.2; 95% CI, 1.2-3.9) was found to be significantly higher in patients treated with UPA than in patients receiving TOFA. UPA was also associated with around 2-fold higher odds of reaching both CR (95% CI, 1.3-4.3; 95% CI, 1.0-3.4) and biochemical remission (95% CI, 1.3-4.4; 95% CI, 1.2-4.0) at the same timepoints compared with TOFA. No significant differences were seen in IBD-related hospitalization and early colectomy rates between the 2 treatment groups. No new safety signal was noted. CONCLUSIONS: UPA might be associated with better short- and mid-term clinical and biochemical outcomes compared with TOFA in refractory, moderate-to-severe UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Farkas B, Resál T, Lakatos PL, et al. Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2025. PMID: 40935095. doi:10.1016/j.cgh.2025.06.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。